{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:12:14Z","timestamp":1780085534890,"version":"3.54.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctrv.2025.103063","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:09:45Z","timestamp":1764781785000},"page":"103063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Endocrine-based strategies after CDK4\/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"142","author":[{"given":"Alicia","family":"Escudero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"Papakonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"L\u00f3pez de S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Matikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctrv.2025.103063_b0005","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.ctrv.2025.103063_b0010","article-title":"Comparative long-term outcomes of first-line CDK4\/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+\/HER2-metastatic or advanced breast cancer: a meta-analysis","volume":"25","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103063_b0015","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103063_b0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"35","key":"10.1016\/j.ctrv.2025.103063_b0025","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.21.01374","article-title":"Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update","volume":"39","author":"Moy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ctrv.2025.103063_b0030","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103063_b0035","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103063_b0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103063_b0045","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103063_b0050","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"31","author":"Campone","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103063_b0055","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S1470-2045(24)00373-5","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103063_b0060","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"25","author":"Rugo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103063_b0065","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103063_b0070","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103063_b0075","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 Inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103063_b0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103063_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103063_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"1","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ctrv.2025.103063_b0095","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. Oct 18 2011;343:d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"10.1016\/j.ctrv.2025.103063_b0100","unstructured":"European Society for Medical Oncology (ESMO). ESMO Metastatic Breast Cancer Living Guideline. v1.2, April 2025. Available from: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer."},{"issue":"27","key":"10.1016\/j.ctrv.2025.103063_b0105","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.22.01063","article-title":"Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update","volume":"40","author":"Henry","year":"2022","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103063_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103063_b0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103063_b0120","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression","volume":"41","author":"Evrenoglou","year":"2022","journal-title":"Stat Med"},{"issue":"7\u20138","key":"10.1016\/j.ctrv.2025.103063_b0125","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2025.103063_b0130","series-title":"The Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.ctrv.2025.103063_b0135","doi-asserted-by":"crossref","unstructured":"Chia S, Redfern A, Ayoub JP, et al. A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2 negative and estrogen receptor positive breast cancer following progression on first line CDK 4\/6 inhibitor and aromatase inhibitos: The CCTG\/BTC MA.40\/FINER Study. JCO 43, LBA1005-LBA1005(2025). Presented at ASCO annual meeting 2025.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1005"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103063_b0140","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO-24-01865","article-title":"Second-line endocrine therapy with or without palbociclib rechallenge in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: PALMIRA trial","volume":"43","author":"Llombart-Cussac","year":"2025","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103063_b0145","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2025.103063_b0150","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"Mayer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103063_b0155","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103063_b0160","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors - efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103063_b0165","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1078-0432.CCR-21-2652","article-title":"Sapanisertib plus fulvestrant in postmenopausal women with estrogen receptor-positive\/HER2-negative advanced breast cancer after progression on aromatase inhibitor","volume":"28","author":"Garc\u00eda-S\u00e1enz","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103063_b0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","article-title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","volume":"32","author":"Dent","year":"2021","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103063_b0175","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103063_b0180","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103063_b0185","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS12-08","article-title":"Abstract PS12-08: MORPHEUS hormone receptor-positive breast cancer: interim analysis of a phase Ib\/II, study of fulvestrant \u00b1 atezolizumab and abemaciclib triplet treatment in patients metastatic disease","volume":"84","author":"Jung","year":"2024","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.ctrv.2025.103063_b0190","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103063_b0195","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Layman RM, Curigliano G, et al. Gedatolisib plus fulvestrant, with & without palbociclib, vs fulvestrant in patients with HR+\/HER2-\/PIK3CA wild-type advanced breast cancer: first results from VIKTORIA-1. Presented at: ESMO Congress 2025; October 17-21, 2025; Berlin, Germany. Abstract LBA17.","DOI":"10.1016\/j.annonc.2025.09.027"},{"key":"10.1016\/j.ctrv.2025.103063_b0200","unstructured":"Mayer EL, Tolaney SM, Mart\u00edn M, et al. Giredestrant plus everolimus vs endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4\/6 inhibitor: primary results of the Phase III evERA BC trial. Presented at: ESMO Congress 2025; October 17-21, 2025; Berlin, Germany. Abstract LBA16."},{"issue":"6","key":"10.1016\/j.ctrv.2025.103063_b0205","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103063_b0210","doi-asserted-by":"crossref","unstructured":"Pistilli B, Sohn J, Schmid P, et al. OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4\/6 inhibitors. J Clin Oncol 43, TPS1131-TPS1131 (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1131"},{"key":"10.1016\/j.ctrv.2025.103063_b0215","doi-asserted-by":"crossref","unstructured":"Goetz MP, Wander SA, Bachelot, T, et al. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+\/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. J Clin Oncol 42, TPS1127-TPS1127 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1127"},{"issue":"17","key":"10.1016\/j.ctrv.2025.103063_b0220","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103063_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.621","article-title":"CAPItello-292: a phase 1b\/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+\/HER2\u2212 advanced breast cancer","author":"Hamilton","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103063_b0230","doi-asserted-by":"crossref","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N, et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature. 2024 Dec;636(8042):474-480. Epub 2024 Nov 27. Erratum in: Nature. 2025 Aug;644(8076):E32.","DOI":"10.1038\/s41586-024-08035-2"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103063_b0235","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41467-025-55914-x","article-title":"Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4\/6 inhibitors","volume":"16","author":"Kan","year":"2025","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103063_b0240","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.3390\/ijms26157300","article-title":"Genomic predictive biomarkers in breast cancer: the haves and have nots","volume":"26","author":"Beecher","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103063_b0245","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103063_b0250","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103063_b0255","unstructured":"ASCENT-07 (NCT05840211). A randomized, open-label, global study evaluating sacituzumab govitecan versus treatment of physician\u2019s choice chemotherapy in patients with HR+\/HER2\u2013 inoperable, locally advanced or metastatic breast cancer who have received endocrine therapy and are eligible for first-line chemotherapy. ClinicalTrials.gov identifier: NCT05840211."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103063_b0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/curroncol32010053","article-title":"Systematic review and network meta-analysis on treating hormone receptor-positive metastatic breast cancer after CDK4\/6 inhibitors","volume":"32","author":"Pathak","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2025.103063_b0265","doi-asserted-by":"crossref","unstructured":"Ravani LV, Calomeni P, Vilbert M, et al. Efficacy of Subsequent Treatments After Disease Progression on CDK4\/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer. JCO Oncol Pract. 2024 Dec 17:OP2400649.","DOI":"10.1200\/JCO.2024.42.16_suppl.1065"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103063_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105808","article-title":"Cyclin-dependent kinase 4\/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)","volume":"10","author":"de Almeida","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.103063_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103535","article-title":"Efficacy and safety of systemic therapies following progression on CDK4\/6 inhibitors in patients with HR+\/HER2\u2013 metastatic breast cancer: a systematic review and network meta-analysis","volume":"89","author":"Buonaiuto","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103063_b0280","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:02:25Z","timestamp":1767168145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S0305737225001859"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103063","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine-based strategies after CDK4\/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103063"}}